NCT03683498 and NCT05095649 are using enriched CD25hi T cells (Tregs) from CD8 and/or CD19 pre-depleted leukapheresis products, which have been shown to be an effective and safe way to prevent GVHD [28] for patients who did not achieve remission after ruxolitinib. The gene discussed is CD8A; the disease is graft versus host disease.